Regulus Therapeutics Inc.

DB:7RG0 Stock Report

Market Cap: €95.9m

Regulus Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:7RG0 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
25 Jul 24Buy€6,704Kathryn CollierIndividual4,000€1.68
18 Jan 24Sell€5,992Crispina CalsadaIndividual5,468€1.10

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 7RG0?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,106,1971.69%
Hedge Funds4,263,7016.51%
General Public6,887,20510.5%
VC/PE Firms11,467,80217.5%
Institutions41,775,22963.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 223.9%.


Top Shareholders

Top 25 shareholders own 86.17% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.6%
Federated Hermes, Inc.
12,852,654€18.8m0%0.05%
9.87%
New Enterprise Associates, Inc.
6,467,802€9.5m0%0.53%
7.63%
Vivo Capital, LLC
5,000,000€7.3m0%0.66%
6.51%
Octagon Capital Advisors LP
4,263,701€6.2m0%1.08%
6.24%
The Vanguard Group, Inc.
4,088,760€6.0m0.94%no data
6.23%
BlackRock, Inc.
4,081,038€6.0m2.83%no data
4.98%
Deep Track Capital, LP
3,262,564€4.8m0%0.16%
3.28%
T. Rowe Price Group, Inc.
2,151,071€3.1m10,400%no data
3.05%
Adage Capital Management, L.P.
2,000,000€2.9m0%0.01%
1.97%
Millennium Management LLC
1,291,415€1.9m6.24%no data
1.96%
Geode Capital Management, LLC
1,280,567€1.9m-3.97%no data
1.76%
Victory Capital Management Inc.
1,155,516€1.7m0%no data
1.58%
Alyeska Investment Group, L.P.
1,037,500€1.5m10.7%0.01%
1.53%
State Street Global Advisors, Inc.
1,000,998€1.5m3.46%no data
1.49%
Stelios Papadopoulos
978,388€1.4m0%no data
1.45%
Woodline Partners LP
948,702€1.4m0.11%0.01%
1.37%
Dafna Capital Management, LLC
895,200€1.3m0%0.38%
1.36%
Point72 Asset Management, L.P.
893,762€1.3m0%no data
1.17%
RA Capital Management, L.P.
766,834€1.1m-87.7%0.02%
0.82%
Opaleye Management Inc.
535,000€783.1k-63.7%0.14%
0.76%
Northern Trust Global Investments
497,304€727.9k188%no data
0.5%
FMR LLC
328,157€480.4k-83.8%no data
0.46%
TD Asset Management, Inc.
302,000€442.1k0%no data
0.28%
Sarissa Capital Management LP
185,183€271.1k0%0.07%
0.27%
Goldman Sachs Group, Investment Banking and Securities Investments
179,005€262.0k29.3%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 21:40
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regulus Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets U.S. (Historical)
Madhu KumarB. Riley Securities, Inc.